Department of Surgical Pathology, Hyogo Medical University School of Medicine, Nishinomiya, Japan.
Department of Pathology, The First People's Hospital of Foshan, Foshan, Republic of China.
Pathol Int. 2023 May;73(5):181-187. doi: 10.1111/pin.13315. Epub 2023 Feb 24.
Approximately 40 families with multiple gastrointestinal stromal tumors (GISTs) and germline c-kit gene mutations have been reported. Three knock-in mouse models have been generated, and all the models showed a cecal GIST. In the present study, we established a cell line derived from cecal GIST in a familial GIST model mouse with KIT-Asp818Tyr. Since the established cells showed spindle-shaped morphology with atypical nuclei, and since immunohistochemistry revealed that they were positive for α-SMA but negative for KIT, CD34 and desmin, the phenotypes of the cells were reminiscent of dedifferentiated GIST-like ones but not the usual GIST-like ones. Gene expression analysis showed that the cell line, designated as DeGISTL1 cell, did not express c-kit gene apparently, but highly expressed HSP90 families and glutaminase 1. Pathway analysis of the cells revealed that metabolic pathway might promote their survival and growth. Pimitespib, a heat shock protein 90α/β inhibitor, and Telaglenastat, a selective glutaminase 1 inhibitor, inhibited proliferation of DeGISTL1 cells and the combination of these showed an additive effect. DeGISTL1 cells might be a good model of dedifferentiated GISTs, and combination of Pimitespib and Telaglenastat could be a possible candidate for treatment strategy for them.
约 40 个家族性胃肠道间质瘤(GIST)和胚系 c-kit 基因突变的家族已经被报道。已经产生了三种基因敲入小鼠模型,所有模型均显示出盲肠 GIST。在本研究中,我们在携带 KIT-Asp818Tyr 的家族性 GIST 模型小鼠中建立了源自盲肠 GIST 的细胞系。由于建立的细胞表现出具有非典型核的梭形形态,并且免疫组织化学显示它们对 α-SMA 呈阳性但对 KIT、CD34 和结蛋白呈阴性,因此细胞的表型类似于去分化的 GIST 样但不是通常的 GIST 样。基因表达分析表明,该细胞系命名为 DeGISTL1 细胞,显然不表达 c-kit 基因,但高度表达 HSP90 家族和谷氨酰胺酶 1。对细胞的通路分析表明,代谢通路可能促进它们的存活和生长。Pimitespib,一种热休克蛋白 90α/β 抑制剂,和 Telaglenastat,一种选择性谷氨酰胺酶 1 抑制剂,抑制 DeGISTL1 细胞的增殖,并且联合使用具有相加作用。DeGISTL1 细胞可能是去分化 GIST 的良好模型,Pimitespib 和 Telaglenastat 的联合可能是它们的一种治疗策略候选。